Leung E, Shenton B K, Green K, Jackson G, Gould F K, Yap C, Talbot D
Department of Surgery, Medical School, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK.
Transpl Infect Dis. 2004 Dec;6(4):156-64. doi: 10.1111/j.1399-3062.2004.00073.x.
Epstein-Barr virus (EBV) is recognised as one of the causative agents for most cases of post-transplant lymphoproliferative disease (PTLD). Elevated levels of EBV DNA are known to be associated with the onset of PTLD, but little information is available regarding how EBV loads change with time in asymptomatic transplant recipients following transplantation. Our aims were to study the trend of EBV loads in renal (RTx), hepatic, and cardiothoracic transplant recipients and to compare their EBV loads with other healthy and patient controls.
A prospective study was performed using a real-time TaqMan polymerase chain reaction technique to measure EBV DNA loads from three types of organ transplant recipients and haemodialysis patients (HD). Their results were then compared with those from the healthy controls (HC); monospot test negative (MN-) and infectious mononucleosis positive (IM+) patients; patients who were previously treated for PTLD (pPTLD); those who were currently diagnosed to have PTLD (PTLD+); and patients who had a stable renal, hepatic, or cardiothoracic graft for more than a year.
Post-transplant EBV loads were significantly higher than the pre-transplant levels. Asymptomatic transplant recipients were differentiated from the PTLD+group at 600 genome copies of EBV/mug DNA, and from IM+group at 100 genome copies. Both HC and MN- groups had significantly lower EBV loads than the three transplant groups. The dynamic change of EBV loads in RTx was greater in the first post-transplant month when compared with the HD group. All transplant recipients had transient rises of EBV loads whereas EBV load continued to rise in one suspected PTLD patient.
Asymptomatic transplant recipients had higher baseline post-transplant EBV levels than the non-transplant and MN- groups. The rising post-transplant EBV load in these transplant recipients did not seem to be sustained for longer than 2 weeks. However, in a PTLD+patient the rising EBV load continued over a period of 4 weeks. Hence, the dynamic pattern of EBV loads is more important than absolute EBV DNA measurements alone in identifying those who might go on to develop PTLD.
爱泼斯坦-巴尔病毒(EBV)被认为是大多数移植后淋巴细胞增生性疾病(PTLD)病例的致病因素之一。已知EBV DNA水平升高与PTLD的发病有关,但关于无症状移植受者移植后EBV载量随时间如何变化的信息却很少。我们的目的是研究肾移植(RTx)、肝移植和心胸移植受者中EBV载量的变化趋势,并将他们的EBV载量与其他健康对照和患者对照进行比较。
采用实时TaqMan聚合酶链反应技术进行前瞻性研究,以测量三种器官移植受者和血液透析患者(HD)的EBV DNA载量。然后将他们的结果与健康对照(HC)、嗜异性凝集试验阴性(MN-)和传染性单核细胞增多症阳性(IM+)患者、既往接受过PTLD治疗的患者(pPTLD)、目前诊断为PTLD的患者(PTLD+)以及肾、肝或心胸移植稳定超过一年的患者的结果进行比较。
移植后EBV载量显著高于移植前水平。无症状移植受者与PTLD+组在EBV/μg DNA 600基因组拷贝时区分开来,与IM+组在100基因组拷贝时区分开来。HC组和MN-组的EBV载量均显著低于三个移植组。与HD组相比,RTx中EBV载量在移植后的第一个月变化更大。所有移植受者的EBV载量均有短暂升高,而一名疑似PTLD患者的EBV载量持续升高。
无症状移植受者移植后的基线EBV水平高于非移植组和MN-组。这些移植受者移植后EBV载量的上升似乎不会持续超过2周。然而,在一名PTLD+患者中,EBV载量在4周内持续上升。因此,在识别可能发展为PTLD的患者时,EBV载量的动态模式比单独的绝对EBV DNA测量更为重要。